AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 272.42B +28.4% |
| Revenue (ttm) | 50.03B +8.6% |
| Net Income | 8.71B +45.3% |
| EPS | 5.57 +45.3% |
| Shares Out | n/a |
| PE Ratio | 31.28 |
| Forward PE | 19.71 |
| Dividend | 2.71 (1.69%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | n/a |
| Average Volume | 841 |
| Open | 160.70 |
| Previous Close | 160.70 |
| Day's Range | 160.70 - 160.70 |
| 52-Week Range | 113.25 - 180.45 |
| Beta | n/a |
| RSI | 64.44 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices
New tax will hit branded drugs and active ingredients while exempting generics for at least one year
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
AstraZeneca (AZN) Avoids Tariffs with Increased U.S. Commitment
AstraZeneca (AZN) Avoids Tariffs with Increased U.S. Commitment
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial
AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common liver cancer lived before their disease worsen...
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report
The Trump administration is reportedly preparing to announce 100% tariffs on pharmaceutical companies that have not secured pricing deals with the White House . The announcement could come as soon as ...
AstraZeneca: Imfinzi, Imjudo Combo With Lenvatinib And TACE Show Positive Phase III Trial Results
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday positive high-level results from its EMERALD-3 Phase III trial of Imfinzi (durvalumab) in combination with Imjudo (tremel...
AstraZeneca Scores Pediatric Win While Adult Trial Falls Short In Rare Bone Disease
AstraZeneca reports mixed Phase 3 data for efzimfotase alfa in HPP and positive COPD results for tozorakimab; shares rise on updates. ... Full story available on Benzinga.com
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
The company said the results support the drug's potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.
AstraZeneca: Efzimfotase Alfa Shows Positive Results From Phase III Programme
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the efzimfotase alfa or ALXN1850 Phase III clinical programme, designed to study a broad hypophosphatasia patient population, demonstrated pos...
If You Invested $1000 In AstraZeneca Stock 10 Years Ago, You Would Have This Much Today
AstraZeneca (NYSE: AZN) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average annual return of 13.13%. Currently, AstraZeneca has a market capitaliza...
AstraZeneca stock jumps as COPD drug trial win surprises market
Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its experimental chronic obstructive pulmonary disease (COPD) treatment, tozorakim...
AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study
(RTTNews) - Shares of AstraZeneca PLC (AZN) are gaining about 4 percent on Friday morning trading after the company announced positive high-level results from the Phase III OBERON and TITANIA trials i...
Stocks to Watch: Unity, Carnival, AstraZeneca
AstraZeneca Zips Higher On Its Double Win In COPD Treatment
AstraZeneca stock jumped Friday after the U.K.-based drugmaker said its COPD drug succeeded in two final-phase studies.
AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstru...
AstraZeneca Strengthens Position In COPD Race With Successful Trials
AstraZeneca reports Phase 3 success for tozorakimab in COPD, reducing exacerbations and showing strong safety across broad patient groups. ... Full story available on Benzinga.com
Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more
These are the stocks posting the largest moves premarket.
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduce...
AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients' symptoms worsened, the company said.
AstraZeneca's Tozorakimab Meets Primary Endpoint In Phase III COPD Trials
(RTTNews) - AstraZeneca Plc. (AZN, AZN.L, ZEG.DE, AZN.ST) announced positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COP...
AstraZeneca drug reduces COPD flare ups in late-stage trials
AstraZeneca said on Friday said its experimental treatment tozorakimab met the main goal in two late-stage trials and showed a meaningful reduction in flare ups of chronic obstructive pulmo...
Final Trade: AZN, VIX, IWM
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.